PUBLICACIÓN

Clinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine Therapy

Logo Open Access

ACCEDER A LA PUBLICACIÓN: Scopus Orcid

Eadon M.T. et al.


CITAS

0

DOI

10.1002/cpt.70071

EID

2-s2.0-105016631276

ISSN

0009-9236

EISSN

1532-6535

BIBTEX

@article{Agundez2025,title = {Clinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine Therapy},journal = {Clinical Pharmacology and Therapeutics},year = {2025},author = {Eadon, M.T. and Hein, D.W. and Andersen, M.A. and Chapman, A.B. and Cooper-DeHoff, R.M. and Desta, Z. and Duarte, J.D. and Elchynski, A.L. and Gaedigk, A. and Karol, S.E. and Limdi, N.A. and Lteif, C. and Sosinski, L. and Zubiaur, P. and Whirl-Carrillo, M. and Klein, T.E. and Caudle, K.E. and Donnelly, R.S. and Ag{\'u}ndez, J.A.G.}}


AUTORES DE LA UEX